Amplity Health’s Post

In this episode of Russo Partners' Conversations that Matter video, Pete O'Heeron, CEO of FibroBiologics (Nasdaq: FBLG), shares the challenges and excitement of advancing fibroblast technology. Pete emphasizes the importance of strong science and proper capitalization to push innovative treatments forward. Learn more about how FibroBiologics is working to address diabetic foot ulcers and other chronic diseases with rigorous, repeatable science. 🎥 https://lnkd.in/ef3J_Msb #HealthcareInnovation #RegenerativeMedicine #ChronicDisease

A painful rare disease where calcium builds up in the arteries could be treated with an obvious drug that had been overlooked for years. Etidronate, a drug that reduces calcium absorption, is used in various bone diseases. Given this rare disease (ACDC) has an excessive calcium issue, it seems obvious that etidronate would be a perfect fit. But because it's a cheap, old drug, with no financial incentives, no one took the initiative to repurpose it. Recently, an amazing team at the NIH decided to pick it up and conduct a clinical trial. The results look really promising. At Every Cure, we see this as an example of low-hanging fruit: we understand the disease, we understand the drug, and there's a perfect match between them. However, no one is pursuing these opportunities because there's no profit to be made. This is where Every Cure steps in, identifying such opportunities and moving them forward. #DrugRepurposing #HealthcareInnovation #RareDiseases #MedicalBreakthroughs #PatientCares

Innovative #biomarkers and technologies, such as #PCR and next-generation #sequencing, are enhancing diagnostic accuracy and enabling personalized treatment approaches. As awareness of early diagnosis and individualized care increases, the market is poised for significant expansion, particularly in regions like Asia-Pacific and #LatinAmerica. The global in-vitro inflammatory bowel disease (IBD) diagnostics market is projected to grow from US$ 1.6 billion in 2023 to over US$ 2.9 billion by 2034, at a CAGR of 5.6%. This growth is driven by the rising incidence of Crohn’s disease and ulcerative colitis, coupled with advancements in non-invasive diagnostic techniques and the increasing use of point-of-care testing (POCT). Visit - https://lnkd.in/dX5KYDeR

Have you heard about the CHOLYSER technology? Renatus is at the forefront of this innovative approach. The research and development efforts are dedicated to finding novel, safe cyclodextrins (CDs) and leveraging their unique properties to target various diseases. The #CHOLYSER™ CDs exhibit exceptional abilities to preferentially and effectively encapsulate non-membranous cholesterol. Compared to hashtag HPβCD (hydroxypropyl-beta-cyclodextrin), which is under clinical trials for several diseases, CHOLYSER™ CDs offer not only improved cholesterol-lowering effects but also superb safety profiles, providing a powerful means of modulating cholesterol metabolism with a wider therapeutic window. By focusing on these advanced "cholesterol modulators", or "cholesterol-lowering agents", we aim to address the unmet medical need for effective cholesterol intervention, significantly improving patient outcomes and advancing the treatment of cholesterol-related diseases. CarboHyde is proud to be Renatus's strategic R&D partner in bringing novel cyclodextrin-based solutions closer to the market. #cholesterol #drugdevelopment #medicine

On #WorldPsoriasisDay and every day, we’re committed to advancing research and enhancing the lives of those living with psoriasis. While the cause of this disease remains unclear and there currently is no cure, our psoriasis, generalized pustular psoriasis, and psoriatic arthritis registries provide crucial steps forward in advancing our understanding the condition. By analyzing vast #datasets on treatments and patient experiences, we provide our pharma partners with evidence-based insights to guide research and improve the patient journey. Check out our #psoriasis related registries and learn how you can be part of the solution >> https://hubs.la/Q02W0n530 #PsoriasisAwareness #PatientExperience #ClinicalResearch #RWD

Triple therapy for Class III/IV lupus nephritis: Glucocorticoid plus 1. mycophenolate plus belimumab, or 2. mycophenolate plus calcineurin inhibitor, or 3. low dose cyclophosphamide plus belimumab.

On #WorldPsoriasisDay and every day, we’re committed to advancing research and enhancing the lives of those living with psoriasis. While the cause of this disease remains unclear and there currently is no cure, our psoriasis, generalized pustular psoriasis, and psoriatic arthritis registries provide crucial steps forward in advancing our understanding the condition. By analyzing vast #datasets on treatments and patient experiences, we provide our pharma partners with evidence-based insights to guide research and improve the patient journey. Check out our #psoriasis related registries and learn how you can be part of the solution >> https://hubs.la/Q02W0x0H0 #PsoriasisAwareness #PatientExperience #ClinicalResearch #RWD

Living with Inflammatory Bowel Disease (IBD) can be challenging, but new advancements are helping to make diagnosis and monitoring less invasive.    Intestinal ultrasound—a non-invasive tool—is changing the game for patients with Crohn's disease and ulcerative colitis, offering real-time insights into the bowel's condition without the need for scopes or biopsies.    Read our latest article to learn how this innovation is already improving the quality of life for many by making care more accessible and less intrusive: https://lnkd.in/e8B_J8hH   #IBD #CrohnsDisease #UlcerativeColitis     Pfizer

📄 𝐑𝐢𝐛𝐨𝐡𝐲𝐚𝐥 𝐃𝐫𝐨𝐩𝐬: 𝐓𝐡𝐞 𝐍𝐞𝐰 𝐏𝐚𝐩𝐞𝐫 We are proud to announce that the latest study on our Ribohyal drops, based on our NCE Ribohyal (Har®, 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝐻𝑦𝑎𝑙𝑢𝑟𝑜𝑛𝑖𝑐 𝐴𝑐𝑖𝑑), has just been accepted for publication in the Heliyon Journal 🎯 The study evaluated the 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐨𝐟 𝐑𝐢𝐛𝐨𝐡𝐲𝐚𝐥 compared to hyaluronic acid eye drops in patients with dry eye disease, confirming the advantages of our NCE: ✔️ OSDI and Osmolarity showed better improvements in the Ribohyal group ✔️Among the OSDI parameters, photophobia was more effectively improved in the Ribohyal group ✔️ The presence of Riboflavin in the NCE can improve the recovery and protection in DED patients ✔️ Ribohyal effectively reduced DED symptoms and improved photophobia within two hours of instillation, lasting up to 8 weeks. Stay tuned for more information #DryEyeDisease #MedicalResearch #EyeCare

Osteoarthritis is a leading cause of chronic pain and reduced mobility, impacting millions worldwide. 😔 But there’s exciting research on the horizon! Enter Placenta Derived Protein Array (PDPA) — a promising new avenue in the treatment of degenerative joint diseases like osteoarthritis. PDPA’s regenerative properties have the potential to help reduce inflammation, alleviate pain, and even improve joint mobility. 🌟 Imagine a treatment that doesn’t just manage symptoms but addresses the underlying causes of joint deterioration. While we’re still learning about the full impact of PDPA, early studies suggest it could offer a more effective, non-invasive option for patients struggling with joint issues. 🙌🏽 Could PDPA offer relief where traditional treatments have fallen short? The future of joint care might be closer than we think. 💡 #PDPA #Osteoarthritis #JointHealth #RegenerativeMedicine #ChronicPain #InflammationRelief #MobilityMatters #HealthInnovation #PatientCare #DegenerativeDiseases #MedicalBreakthrough